Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorEl-Khazragy N.
dc.contributor.authorElshimy A.A.
dc.contributor.authorHassan S.S.
dc.contributor.authorMatbouly S.
dc.contributor.authorSafwat G.
dc.contributor.authorZannoun M.
dc.contributor.authorRiad R.A.
dc.contributor.otherDepartment of Clinical Pathology and Hematology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAin Shams Medical Research Institute (MASRI)
dc.contributor.otherAin Shams University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Former Department of Biomedical Research
dc.contributor.otherArmed Forces College of Medicine (AFCM)
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Medical Microbiology and Immunology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherCairo University
dc.contributor.otherNew Giza University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Clinical Pathology
dc.contributor.otherNational Cancer Institute
dc.contributor.otherCairo University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Pediatrics
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAin Shams University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Cancer Biology
dc.contributor.otherFaculty of Biotechnology
dc.contributor.otherOctober University for Modern Sciences and Art (MSA) University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Pediatrics
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAl Azhar University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Biotechnology and Molecular Biology
dc.contributor.otherGlobal Research Lab
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:40:38Z
dc.date.available2020-01-09T20:40:38Z
dc.date.issued2019
dc.descriptionScopus
dc.descriptionMSA Google Scholar
dc.description.abstractBackground: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.en_US
dc.identifier.doihttps://doi.org/10.1002/jcb.28017
dc.identifier.doiPubMedID
dc.identifier.issn7302312
dc.identifier.otherhttps://doi.org/10.1002/jcb.28017
dc.identifier.otherPubMedID
dc.identifier.urihttps://t.ly/2ddvR
dc.language.isoEnglishen_US
dc.publisherWiley-Liss Inc.en_US
dc.relation.ispartofseriesJournal of Cellular Biochemistry
dc.relation.ispartofseries120
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectUniversity of Modern Sciences and Arts
dc.subjectMSA University
dc.subjectBcl-2en_US
dc.subjectchildhood acute lymphoblastic leukemia (ALL)en_US
dc.subjectmiR-125ben_US
dc.subjectprognostic factorsen_US
dc.subjectantileukemic agenten_US
dc.subjectmicroRNA 125ben_US
dc.subjectprotein bcl 2en_US
dc.subjectacute lymphoblastic leukemiaen_US
dc.subjectArticleen_US
dc.subjectcancer chemotherapyen_US
dc.subjectcancer prognosisen_US
dc.subjectcancer specific survivalen_US
dc.subjectchilden_US
dc.subjectchildhood leukemiaen_US
dc.subjectclinical outcomeen_US
dc.subjectcontrolled studyen_US
dc.subjectdown regulationen_US
dc.subjectfemaleen_US
dc.subjectgene expressionen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectpredictive valueen_US
dc.subjectpriority journalen_US
dc.subjecttreatment responseen_US
dc.titleDysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemiaen_US
dc.typeArticleen_US
dcterms.isReferencedBySiegel, R.L., Miller, K.D., Jemal, A., Cancer statistics (2016) Cancer J Clin, 66 (1), pp. 7-30; Pui, C.H., Recent research advances in childhood acute lymphoblastic leukaemia (2010) J Formos Med Assoc, 109 (11), pp. 777-787; Polakova, K.M., Koblihova, J., Stopka, T., Role of epigenetics in chronic myeloid leukemia (2013) Curr Hematol Malig Rep, 8, pp. 28-36; Bousquet, M., Quelen, C., Rosati, R., Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation (2008) J Exp Med, 205, pp. 2499-2506; Chapiro, E., Russell, L.J., Struski, S., A new recurrent translocation t(11;14)(q24;q32) involving IGH and miR-125b-1 in B-cell progenitor acute lymphoblastic leukaemia (2010) Leukemia, 24 (7), pp. 1362-1364; Sanddhya, N.S., Sachdanandam, P., Thilagavathy, S., Shanthi, P., Role of miR-125b and miR-203 expressions in the pathogenesis of BCR ? /ABL + acute lymphoblastic leukemia (ALL) (2016) Gene Reports, 4, pp. 253-257; Walter, K., Bonifer, C., Tagoh, H., Stem cell specific epigenetic priming and B cell specific transcriptional activation at the mouse Cd19 locus (2008) Blood, 2008 (112), pp. 1673-1682; Li, J., Wan, Y., Ji, Q., Fang, W.Y., The role of microRNAs in B-cell development and function (2013) Cell Mol Immunol, 10, pp. 107-112; Schotte, D., De Menezes, R.X., Moqadam, F.A., MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukaemia (2011) Haematologica, 96 (5), pp. 703-711; Czabotar, P.E., Lessene, G., Strasser, A., Adams, J.M., Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy (2014) Nat Rev Mol Cell Biol, 15, pp. 49-63; Tam, C.S., Seymour, J.F., Roberts, A.W., Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia (2016) Semin Oncol, 43, pp. 274-279. , https://doi.org/10.1053/j.seminoncol.2016.02.014; Koehler, B.C., Scherr, A.L., Lorenz, S., Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro (2013) PLoS One, 8. , https://doi.org/10.1371/journal.pone.0076446; Sun, T., Sun, B., Zhao, X., Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription co-activation by Bcl-2 and Twist1: a study of hepatocellular carcinoma (2011) Hepatology, 54, pp. 1690-1706. , https://doi.org/10.1002/hep.24543; Yang, D., Zhan, M., Chen, T., miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer (2017) Sci Rep, 7, p. 43109. , https://doi.org/10.1038/srep43109; Stary, J., Zimmermann, M., Campbell, M., Intensive chemotherapy for childhood acute lymphoblastic leukaemia: results of the randomized intercontinental trial ALL IC-BFM 2002 (2014) J Clin Oncol, 32 (3), pp. 174-184; Anderson, M.A., Deng, J., Seymour, J.F., The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53- independent mechanism (2016) Blood, 127, pp. 3215-3224; Roberts, A.W., Advani, R.H., Kahl, B.S., Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 + lymphoid malignancies (2015) Br J Haematol, 170, pp. 669-678; Willimott, S., Wagner, S.D., miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells (2012) J Biol Chem, 287, pp. 2608-2617; Wang, F., Yu, D., Liu, Z., miR-125b functions as a tumor suppressor and enhances chemo sensitivity to cisplatin in osteosarcoma (2016) Technol Cancer Res Treat, 15 (6), pp. NP105-NP112; Bartel, D.P., MicroRNAs: target recognition and regulatory functions (2009) Cell, 136, pp. 215-233; Pui, C.H., Mullighan, C.G., Evans, W.E., Relling, M.V., Pediatric acute lymphoblastic leukaemia: where are we going and how do we get there? (2012) Blood, 120 (6), pp. 1165-1174; Calin, G.A., Croce, C.M., MicroRNA signatures in human cancers (2006) Nat Rev Cancer, 6, pp. 857-866; de Oliveira, J.C., Brassesco, M.S., Scrideli, C.A., Tone, L.G., Narendran, A., MicroRNA expression and activity in pediatric acute lymphoblastic leukaemia (ALL) (2012) Pediatr Blood Cancer, 59 (4), pp. 599-604; Sun, Y.M., Lin, K.Y., Chen, Y.Q., Diverse functions of miR-125 family in different cell contexts (2013) J Hematol Oncol, 6, p. 6. , http://www.jhoonline.org/content/6/1/6; Schotte, D., Chau, J.C.K., Sylvester, G., Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukaemia (2009) Leukemia, 23 (2), pp. 313-322; Tili, E., Michaille, J.J., Luo, Z., The down-regulation of miR-125b in chronic lymphocytic leukaemias leads to metabolic adaptation of cells to a transformed state (2012) Blood, 120 (13), pp. 2631-2638; Busch, S., Auth, E., Scholl, F., 5-lipoxygenase is a direct target of miR-19a-3p and miR-125b-5p (2015) J Immunol, 194 (4), pp. 1646-1653; Li, Q., Wu, Y., Zhang, Y., Weiming Li2 miR-125b regulates cell progression in chronic myeloidleukemia via targeting BAK1 (2016) Am J Transl Res, 8 (2), pp. 447-459. , www.ajtr.org; Sun, D., Layer, R., Mueller, A.C., Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells (2014) Oncogene, 33, pp. 1448-1457; Wang, H., Tan, G., Dong, L., Circulating miR-125b as a marker predicting chemoresistance in breast cancer (2012) PLoS One, 7; Nakanishi, H., Taccioli, C., Palatini, J., Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway (2014) Oncogene, 33, pp. 702-712; Hayes, J., Peruzzi, P.P., Lawler, S., MicroRNAs in cancer: biomarkers, functions and therapy (2014) Trends Mol Med, 20, pp. 460-469; Sonoki, T., Iwanaga, E., Mitsuya, H., Asou, N., Insertion of microRNA- 125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukaemia (2005) Leukemia, 19 (11), pp. 2009-2010; Tassano, E., Acquila, M., Tavella, E., Micalizzi, C., Panarello, C., Morerio, C., MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukaemia (2010) Genes Chromosomes Cancer, 49 (8), pp. 682-687; Gefen, N., Binder, V., Zaliova, M., Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukaemias and confers survival advantage to growth inhibitory signals independent of p53 (2010) Leukemia, 24 (1), pp. 89-96; Piatopoulou, D., Avgeris, M., Marmarinos, A., miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment (2017) Br J Cancer, 117, pp. 801-812; Kandi, R., Gutti, U., Saladi, R.G.V., Gutti, R.K., miR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukaemia (2015) Hematol Oncol Stem Cell Ther, 8 (2), pp. 95-97; Klusmann, J.H., Li, Z., Bohmer, K., miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukaemia (2010) Genes Dev, 24 (5), pp. 478-490; Schotte, D., Pieters, R., Den boer, M.L., MicroRNAs in acute leukemias: from biological players to clinical contributors (2011) Leukemia, 26, pp. 1-12; Akbari Moqadam, F., Lange-Turenhout, E.A.M., Ari�s, I.M., Pieters, R., den Boer, M.L., miR-125b, miR-100, and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukaemia (2013) Leuk Res, 37 (10), pp. 1315-1321; Zhang, H., Luo, X.Q., Feng, D.D., Upregulation of microRNA-125b contributes to leukaemogenesis and increases drug resistance in pediatric acute promyelocytic leukaemia (2011) Mol Cancer, 10, p. 108; Zhou, L., Bai, H., Wang, C., Wei, D., Qin, Y., Xu, X., microRNA125b promotes leukaemia cell resistance to daunorubicin by inhibiting apoptosis (2014) Mol Med Rep, 9 (5), pp. 1909-1916; Kong, F., Sun, C., Wang, Z., miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting proapoptotic Bcl-2 antagonist killer 1 (2011) J Huazhong Univ Sci Technolog Med Sci, 31 (4), pp. 543-549; Zhou, M., Liu, Z., Zhao, Y., MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression (2010) J Biol Chem, 285 (28), pp. 21496-21507; Le, M.T.N., Teh, C., Shyh-Chang, N., MicroRNA-125b is a novel negative regulator of p53 (2009) Genes Dev, 23 (7), pp. 862-876; Bousquet, M., Nguyen, D., Chen, C., Shields, L., Lodish, H.F., MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA (2012) Haematologica, 97 (11), pp. 1713-1721; Enomoto, Y., Kitaura, J., Hatakeyama, K., Emu/miR-125b transgenic mice develop lethal B-cell malignancies (2011) Leukemia, 25 (12), pp. 1849-1856; Murray, M., Rushworth, S.A., Zaitseva, L., Bowles, K.M., Macewan, D.J., Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression (2013) Cell Cycle, 12 (13), pp. 2144-2153; Kim, S.W., Ramasamy, K., Bouamar, H., Lin, A.P., Jiang, D., Aguiar, R.C.T., MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alphainduced protein 3 (TNFAIP3, A20) (2012) Proc Natl Acad Sci USA, 109 (20), pp. 7865-7870; Tan, G., Niu, J., Shi, Y., Ouyang, H., Wu, Z.H., NF-kappaB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38 alpha upon ultraviolet radiation (2012) J Biol Chem, 287 (39), pp. 33036-33047; Zeng, C.W., Zhang, X.J., Lin, K.Y., Camptothecin induces apoptosis in cancer cells via microRNA-125b mediated mitochondrial pathways (2012) Mol Pharmacol, 81 (4), pp. 578-586; Bousquet, M., Harris, M.H., Zhou, B., Lodish, H.F., MicroRNA miR-125b causes leukemia (2010) Proc Natl Acad Sci USA, 107, pp. 21558-21563; Chapiro, E., Russell, L.J., Struski, S., A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia (2010) Leukemia, 24, pp. 1362-1364
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty of Biotechnology Research Paper